Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMBOLD Sarcoma 202 of risvutatug rezetecan in previously treated advanced or metastatic sarcomas
jRCT2011260016Phase 2Recruiting
- Sponsor
- GSK
- Start
- Jun 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, open-label trial of risvutatug rezetecan and granulocyte colony-stimulating factor in Bone and soft tissue sarcoma, osteosarcoma (OS) and soft tissue sarcoma (STS) (3 cohorts), sponsored by GSK. Primary endpoints: Progression-free survival rate at week 18 and Confirmed objective response rate. Started Jun 2026; status: recruiting.
02
Drugs
risvutatug rezetecangranulocyte colony-stimulating factor
03
Conditions
Bone and soft tissue sarcomaosteosarcoma (OS)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on jRCT2011260016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011260016.